YU72001A - Kristalni oblici natrijumove soli 5-hloro-2-metoksi-n-(2-(4- metoksi-3-metilaminotiokarbonil-aminosulfonilfenil)etil) benzmida - Google Patents

Kristalni oblici natrijumove soli 5-hloro-2-metoksi-n-(2-(4- metoksi-3-metilaminotiokarbonil-aminosulfonilfenil)etil) benzmida

Info

Publication number
YU72001A
YU72001A YU72001A YUP72001A YU72001A YU 72001 A YU72001 A YU 72001A YU 72001 A YU72001 A YU 72001A YU P72001 A YUP72001 A YU P72001A YU 72001 A YU72001 A YU 72001A
Authority
YU
Yugoslavia
Prior art keywords
methoxy
benzamide
chloro
ethyl
sodium salt
Prior art date
Application number
YU72001A
Other languages
English (en)
Inventor
Heinrich Christian Englert
Uwe Gerlach
Tobias Metzenthin
Herald Schneider
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of YU72001A publication Critical patent/YU72001A/sh
Publication of RS50916B publication Critical patent/RS50916B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • C07C335/42—Sulfonylthioureas; Sulfonylisothioureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ovaj se pronalazak odnosi na kristalne oblike natrijumove soli 5-hloro-2-metoksi-N-(2-(4-metoksi-3-metilaminotiokarbonilaminosulfonilfenil)etil)-benzamida, postupke za njihovo pripremanje, na njihovu upotrebu i na farmaceutske preparate koji ih sadrže.
YUP-720/01A 1999-04-16 2000-04-04 Kristalni oblici natrijumove soli 5-hloro-2-metoksi-n-(2-(4- metoksi-3-metilaminotiokarbonil-aminosulfonilfenil)etil) benzmida RS50916B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19917233A DE19917233A1 (de) 1999-04-16 1999-04-16 Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids

Publications (2)

Publication Number Publication Date
YU72001A true YU72001A (sh) 2004-07-15
RS50916B RS50916B (sr) 2010-08-31

Family

ID=7904803

Country Status (33)

Country Link
US (1) US6723751B1 (sh)
EP (2) EP1637519B1 (sh)
JP (1) JP4662640B2 (sh)
KR (1) KR100700302B1 (sh)
CN (1) CN1168712C (sh)
AR (1) AR023479A1 (sh)
AT (2) ATE414059T1 (sh)
AU (1) AU773246B2 (sh)
BR (1) BR0010658A (sh)
CA (1) CA2370388C (sh)
CZ (1) CZ302459B6 (sh)
DE (3) DE19917233A1 (sh)
DK (1) DK1173418T3 (sh)
EE (1) EE04612B1 (sh)
ES (1) ES2251996T3 (sh)
HK (1) HK1046270B (sh)
HR (1) HRP20010744B1 (sh)
HU (1) HU229082B1 (sh)
IL (2) IL145921A0 (sh)
ME (1) MEP55708A (sh)
MX (1) MXPA01010275A (sh)
MY (1) MY122588A (sh)
NO (1) NO327798B1 (sh)
NZ (1) NZ514788A (sh)
PL (1) PL203809B1 (sh)
RS (1) RS50916B (sh)
RU (1) RU2235089C2 (sh)
SI (1) SI1173418T1 (sh)
SK (1) SK287175B6 (sh)
TR (2) TR200102993T2 (sh)
TW (1) TWI276622B (sh)
WO (1) WO2000063167A1 (sh)
ZA (1) ZA200108400B (sh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289507A1 (en) * 2003-03-17 2011-03-02 Japan Tobacco, Inc. Pharmaceutical compositions of CETP inhibitors
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2098069T3 (es) 1993-02-23 1997-04-16 Hoechst Ag Bencenosulfonil-ureas y -tioureas sustituidas, procedimiento para su preparacion y su utilizacion como agentes farmaceuticos.
DE19505397A1 (de) * 1995-02-17 1996-08-22 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CZ301165B6 (cs) * 1998-09-10 2009-11-25 Sanofi - Aventis Deutschland GmbH Použití benzensulfonyl(thio)mocovin pro lécení a profylaxi dysfunkcí autonomní nervové soustavy a použití benzensulfonyl(thio)mocovin v kombinaci s beta-receptorovými blokátory

Also Published As

Publication number Publication date
DE60024431T2 (de) 2006-07-27
EE200100532A (et) 2002-12-16
NZ514788A (en) 2003-03-28
ATE414059T1 (de) 2008-11-15
EE04612B1 (et) 2006-04-17
KR100700302B1 (ko) 2007-03-29
NO327798B1 (no) 2009-09-28
DE60024431D1 (en) 2006-01-05
JP2002542230A (ja) 2002-12-10
HRP20010744B1 (en) 2010-08-31
SK287175B6 (sk) 2010-02-08
ATE311364T1 (de) 2005-12-15
DK1173418T3 (da) 2006-04-10
CN1354744A (zh) 2002-06-19
MXPA01010275A (es) 2003-07-21
AR023479A1 (es) 2002-09-04
MEP55708A (en) 2011-05-10
CA2370388A1 (en) 2000-10-26
KR20010109355A (ko) 2001-12-08
RU2235089C2 (ru) 2004-08-27
CA2370388C (en) 2009-10-13
EP1637519A1 (en) 2006-03-22
HRP20010744A2 (en) 2003-04-30
HK1046270A1 (en) 2003-01-03
ES2251996T3 (es) 2006-05-16
CZ20013672A3 (cs) 2002-01-16
HK1046270B (zh) 2005-03-11
NO20015014D0 (no) 2001-10-15
PL351245A1 (en) 2003-04-07
US6723751B1 (en) 2004-04-20
EP1173418B1 (en) 2005-11-30
CN1168712C (zh) 2004-09-29
EP1637519B1 (en) 2008-11-12
IL145921A0 (en) 2002-07-25
EP1173418A1 (en) 2002-01-23
WO2000063167A1 (en) 2000-10-26
AU773246B2 (en) 2004-05-20
DE60040811D1 (de) 2008-12-24
BR0010658A (pt) 2002-02-19
TR200501142T2 (tr) 2005-08-22
RS50916B (sr) 2010-08-31
CZ302459B6 (cs) 2011-06-01
MY122588A (en) 2006-04-29
ZA200108400B (en) 2003-04-30
IL145921A (en) 2006-07-05
HUP0200791A2 (hu) 2002-07-29
TWI276622B (en) 2007-03-21
DE19917233A1 (de) 2000-10-19
HUP0200791A3 (en) 2005-04-28
JP4662640B2 (ja) 2011-03-30
AU4542800A (en) 2000-11-02
SI1173418T1 (sl) 2006-02-28
PL203809B1 (pl) 2009-11-30
NO20015014L (no) 2001-10-15
SK14582001A3 (sk) 2002-01-07
TR200102993T2 (tr) 2002-03-21
HU229082B1 (hu) 2013-07-29

Similar Documents

Publication Publication Date Title
YU66101A (sh) Nova jedinjenja i kompozicije kao inhibitori proteaze
ME00558A (en) Pyrazole derivatives for treating hiv
ATE383339T1 (de) Amin-derivate zur behandlung von apoptosis
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
ATE272633T1 (de) Aromatische amiden
BG66085B1 (bg) Фенилаланинови производни
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
ATE326453T1 (de) Antithrombotische amide
NO20031331L (no) Substituerte amino-aza-cykloalkaner anvendelige mot malaria
NO20052520D0 (no) Nye sulfamider
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
ME00454B (me) Nova so perindoprila i farmaceutske kompozicije koje sadrže tu so
SE9901077D0 (sv) Novel use
SE8600413L (sv) Nytt lekemedel och sett att framstella detsamma
NO20025015D0 (no) Et pyridin-1-oksidderivat, og fremgangsmåte for dets overföring til farmasöytisk effektive forbindelser
ATE253359T1 (de) Antithrombotische mittel
YU72001A (sh) Kristalni oblici natrijumove soli 5-hloro-2-metoksi-n-(2-(4- metoksi-3-metilaminotiokarbonil-aminosulfonilfenil)etil) benzmida
HUP0102075A2 (hu) Stabil mitoxantron-oldatok, eljárás az előállításukra
DE69828522D1 (de) Antithrombotische mittel
ATE248163T1 (de) Neuartige, pharmazeutisch aktive verbindung
TR200100906T2 (tr) Trombin inhibitörleri olarak benzamid türevleri
HUP0302860A2 (hu) Nátrium-hidrogén cserélő 1-típusú inhibitor hatású vegyület új etanolátjai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE268768T1 (de) Antithrombosemittel
EP1452522A3 (en) Novel compounds and compositions as protease inhibitors